PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1459.36
Negative P/E while Drug Manufacturers - Specialty & Generic median is 1.49. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
223.64
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.81. Jim Chanos would check for potential asset write-down risks.
-10726.75
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -19.03. Seth Klarman would investigate cash flow improvement potential.
-10726.75
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
223.64
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.79. Jim Chanos would check for valuation bubble risks.
-0.02%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is 0.04%. Seth Klarman would investigate path to profitability.
-0.01%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.10%. Seth Klarman would investigate cash flow improvement potential.